Retatrutide Manufacturer | Supplier – The Most Effective Weight Loss Triple Agonist (Up to c

Retatrutide – The Most Effective Weight Loss Triple Agonist (Up to 71.2 lbs Average Reduction)

Manufacturer | Supplier | Factory – China leading API manufacturer providing high-purity Retatrutide raw material for regulated pharmaceutical research and development.

Retatrutide, developed by Eli Lilly and Company, is an investigational triple hormone receptor agonist that achieved up to 71.2 lbs (32.3 kg) average weight loss in Phase 3 clinical trials. With approximately 28.7% total body weight reduction at the highest studied dose, Retatrutide represents one of the most significant advancements in metabolic and obesity therapeutics currently in development.

What Is Retatrutide?

Retatrutide is a once-weekly injectable peptide therapy designed to simultaneously activate:

• GLP-1 receptors
• GIP receptors
• Glucagon receptors

This triple-agonist mechanism enhances appetite suppression, improves glucose metabolism, and increases energy expenditure—resulting in substantial and sustained weight loss in clinical trials.

Phase 3 Clinical Results – Up to 71.2 lbs Average Weight Loss

In the global Phase 3 TRIUMPH program:

• 12 mg dose: ~28.7% mean body weight reduction (~71.2 lbs)
• 9 mg dose: ~26.4% mean body weight reduction
• Placebo group: ~2.1% reduction

Participants had an average baseline body weight of approximately 248 lbs (112.7 kg). Beyond weight reduction, studies reported improvements in metabolic risk markers and functional outcomes.

These results position Retatrutide among the most potent investigational anti-obesity agents studied to date.

Why Retatrutide May Outperform Single or Dual Agonists

Therapy Type Mechanism Average Weight Reduction

• GLP-1 agonist Appetite suppression ~15%
• Dual agonist (GLP-1/GIP) Appetite + insulin modulation ~20–25%
• Triple agonist (Retatrutide) Appetite + insulin + energy expenditure ~28–29%

By incorporating glucagon receptor activation, Retatrutide may uniquely enhance metabolic rate in addition to reducing caloric intake.

Regulatory Status

Retatrutide remains investigational and has not yet received regulatory approval. Ongoing Phase 3 studies continue evaluating long-term safety, cardiovascular outcomes, and broader metabolic indications.

All procurement and research use must comply with applicable regulatory frameworks in the target jurisdiction.

Retatrutide API Manufacturer & Supplier Information

For pharmaceutical companies, CROs, and peptide development laboratories, sourcing Retatrutide API requires:

• GMP-compliant peptide synthesis facilities
• High purity (≥98%) confirmed by HPLC
• Impurity profiling and stability data
• Batch-level COA documentation
• International export experience

Professional peptide manufacturers and factories in China support global R&D institutions with compliant raw material supply for legitimate pharmaceutical research purposes.

Retatrutide API Technical Overview

• Product Type: Synthetic peptide (triple receptor agonist)
• Dosage Form in Trials: Subcutaneous injection (once weekly)
• Purity Standard: ≥98% (HPLC typical research grade)
• Supply Form: Lyophilized powder (research use)
• Storage Conditions: -20°C recommended

 Global Market Outlook for Triple Agonist Therapies

The obesity therapeutics market is projected to expand significantly over the next decade, driven by:

• Rising global obesity prevalence
• Increased demand for non-surgical weight management
• Cardiometabolic disease burden
• Innovation in peptide engineering

Triple agonist therapies represent the next evolutionary stage beyond GLP-1 and dual incretin-based treatments.

Long-Tail Keyword Expansion (For Ranking Strategy)

• Retatrutide API manufacturer China
• Retatrutide raw material supplier GMP
• Retatrutide triple agonist weight loss 71.2 lbs
• Retatrutide Phase 3 clinical results
• Retatrutide bulk peptide factory
• Retatrutide research grade peptide
• Retatrutide metabolic therapy development
• Retatrutide investigational obesity drug

FAQ

How much weight did Retatrutide reduce in clinical trials?

In Phase 3 studies, Retatrutide achieved up to 71.2 lbs (32.3 kg) average weight loss, equivalent to approximately 28.7% total body weight reduction at the highest dose tested.

Is Retatrutide FDA approved?

Retatrutide is currently investigational and undergoing Phase 3 clinical trials. It has not yet received regulatory approval.

What makes Retatrutide different from GLP-1 drugs?

Unlike single GLP-1 agonists, Retatrutide activates GLP-1, GIP, and glucagon receptors, potentially delivering greater metabolic impact and weight reduction.